期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替罗非班在急性ST段抬高型心肌梗死中的合理应用 被引量：3

Application of Tirofiban in Acute ST-Segment Elevation Myocardial Infarction
下载PDF
导出
摘要 直接经皮冠状动脉介入治疗中尽早、有效、合理的抗血小板治疗无论是对于开通梗死相关冠状动脉还是防止再梗死等临床事件均具有十分重要的意义。替罗非班是一种高选择性非肽类、短效血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂,具有很强抗血小板聚集作用,可与阿司匹林和氯吡格雷联合应用于急性ST段抬高型心肌梗死患者。 It is important to use antiplatelet therapy in the early stages of primary percutaneous coronary intervention for opening the infarct-related coronary artery and/or preventing re-infarction.Tirofiban,a highly selective non-peptide and short-acting platelet glycoprotein Ⅱb/Ⅲa receptor antagonist,can be combined with aspirin and clopidogrel for use in acute ST-segment elevation myocardial infarction as it has a strong antiplatelet aggregation effect.
作者 姜玉蓉 冯彩琴 卢振华
机构地区 三峡大学第一临床医学院宜昌市中心人民医院心内科
出处 《心血管病学进展》 CAS 2010年第6期911-913,共3页 Advances in Cardiovascular Diseases
关键词 血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂 替罗非班 心肌梗死 platelet glycoprotein Ⅱb/Ⅲa receptor antagonist tirofiban myocardial infarction
分类号 R542.22 [医药卫生—心血管疾病] R973.2 [医药卫生—药品]
  • 相关文献

参考文献26

  • 1Mukherjee D,Moliterno DJ.Achieving tissue level perfusion in the setting of acute myocardial infarction[J].Am J Cardiol,2000,85(8A):39C-46C.
  • 2Patrono C,Oller B,fitrCerald CA,et al.Platelet-active drugs:the relationships among dose,effectiveness,and side effects:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2004,126(3 suppl):234s-264s.
  • 3Elliott MA,Marc C,Peter JLMB,et al.The TIMI risk score for unstable angina/non-ST elevation MI:a method for prognostication and therapeutic decision making[J].JAMA,2000,284:835-842.
  • 4The platelet,receptor inhibition for ischemic syndrome management (PRISM)study investigators.A comparison of aspirin plus tirofiban with aspirin plus hepa-rin for unstable angina[J].N Engl J Med,1998,338:1498-1505.
  • 5Lincoff AM.Trial of platelet glycoprotein Ⅱb/Ⅲa receptor antagonists during percutaneous coronary revascularization[J].Am J Cardiol,1998,82:36-42.
  • 6The RESTORE Investigators.Effect of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty[J].Circulation,1997,96:1445-1453.
  • 7Montalescot G,Borentain M,Payot L,et al.Early vs late administration of glycoprotein Ⅱb/Ⅲa inhibition in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction:a meta-analysis[J].JAMA,2004,292:362-366.
  • 8Dobraycki S,Kralisz P,Nowak K,et al.Transfer with GP Ⅱb/Ⅲa inhibitor tirofiban for primary percutaneous coronary intervertion vs.on-site thrombolysis in patients with ST-elevation myocardial infarction(STEMI):a randomized open-label study for patients admitted to community hospitals[J].Eur Heart J,2007,28(20):2438-2448.
  • 9Mockel M,Bocksch W,Strohm S,et al.Facilitated percutaneous coronary intervertion (PCI)in patients with acute ST-elevation myocardial infarction:comparison of prehospital tirofiban versus fibrinolysis before direct PCI[J].Int J Cardiol,2005,103(2):193-200.
  • 10Brener SJ,Barr LA,Burchenal JE,et al.Randomized,placebo-controlled trial of platelet glycoprotein Ⅱb/Ⅲa blockade with primary angioplasty for acute myocardial infarction.ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators[J].Circulation,1998,98:734-741.

二级参考文献21

  • 1Kim JH,Jeong MH,Rhew JY,et al.Long-term clinical outcomes of platelet glycoprotein Ⅱb/Ⅲa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.Circ J,2005,69:159-164.
  • 2Vorehheiner DA,Badimon JJ,Fuster V.Platelet glycoprotein Ⅱb/Ⅲa receptor antagonists in cardiovascular disease.JAMA,1999,281:1407-1414.
  • 3PIatelet Receptor Inhibition in Ischemic Syndmme Management (PRISM)Study Investigators.A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.N Eng J Med,1998,338:1498-1505.
  • 4JamesC.Bleeding complications of glycoprotein Ⅱb/Ⅲa receptor inhibitors.Am Heart J.1999,138:S287-294.
  • 5Jarvis B,Simpson K.Clopidngrel:a review of its use in the prevention of atherothrombosis.Drugs,2000,60:347-358.
  • 6Boersma E,Harrington RA,Molitemo DJ,et al.Platelet glycoprotein Ⅱb/Ⅲa inhibitors in acute coronary syndromes.Lancet,2002,359:189-198.
  • 7Lindahl B,Venge P,Wallentin L.Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease.Cireulation.1996.93:1651-1657.
  • 8Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1) [ J ]. N Engl J Med, 1992, 326(4) :242 -250.
  • 9Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina ) [ J ]. J Am CoU Cardiol, 2002, 40 ( 7 ) : 1366 - 1374.
  • 10Sabatine MS, Morrow DA, Giugliano RP, et al. Implication of Upstream Glycoprotein Ⅱb/Ⅲa Inhibition and Coronary Artery Stenting in the Invasive Management of Unstable Angina/Non-ST-ElevationMyocardial Infraction A Comparison of the Thrombolysis In Myocardial Infarction(TIMI) IIIB Trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy(TACTICS)-TIMI18 rial[J]. Circulation, 2004, 109(7) :874 -80.

共引文献35

同被引文献29

心血管病学进展
2010年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部